Two big pharma execs share the same challenges, but compensation? They’re not even close
Big Pharma execs may share big concerns like the battle over drug pricing, big patent cliffs and the dilemma over pipeline productivity, but they don’t get paid the same.
A brief glimpse of 2 new SEC filings from AbbVie $ABBV and Sanofi $SNY underscore the chasm of wealth that can separate peers in this lofty realm.
AbbVie CEO Richard Gonzalez bagged a package worth a total of $21.3 million for 2018, down slightly from $22.6 million from the year before. R&D chief Michael Severino took home compensation worth $8.6 million. And that’s more than Sanofi CEO Olivier Brandicourt made.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.